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Immune checkpoint regulators are critical modulators
of the immune system, allowing the initiation of a
productive immune response and preventing
the onset of autoimmunity. Co-inhibitory and
co-stimulatory immune checkpoint receptors are
required for full T-cell activation and effector functions
such as the production of cytokines. In autoimmune
rheumatic diseases, impaired tolerance leads to
the development of diseases such as rheumatoid
arthritis, systemic lupus erythematosus, and Sjogren’s
syndrome. Targeting the pathways of the inhibitory
immune checkpoint molecules CD152 (cytotoxic T
lymphocyte antigen-4) and CD279 (programmed
death-1) in cancer shows robust anti-tumor responses
and tumor regression. This observation suggests that,
in autoimmune diseases, the converse strategy of
engaging these molecules may alleviate inflammation
owing to the success of abatacept (CD152-Ig) in
rheumatoid arthritis patients. We review the preclinical
and clinical developments in targeting immune
checkpoint regulators in rheumatic disease.ses [8,9]. Manipulating the CD279 pathway has beenIntroduction
Rheumatic diseases include inflammatory disorders that
cause pain, inflammation, or damage in joints and other
organs, resulting in significant morbidity, mortality, and
societal costs. Examples that are felt to be the result of
autoimmunity include rheumatoid arthritis (RA), juvenile
idiopathic arthritis (JIA), systemic lupus erythematosus
(SLE), psoriasis, systemic sclerosis (SSc), and Sjogren’s syn-
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months following its publication. After this time
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creativecommons.org/publicdomain/zero/1.0/)the net result of molecular pathways that enhance or tem-
per immunity. Both genetic and environmental factors
control these pathways and can influence the development
and severity of these diseases. Beyond engagement of the
innate immune system, the perpetuation and amplification
of these pathologic processes requires signaling through
the B-cell or T-cell receptor, followed by subsequent
ligand interactions delivering co-stimulatory and/or co-
inhibitory signals. These secondary signals are critical in
determining cellular effector functions and modulating
immunity to maintain homeostasis [1]. Co-stimulatory
and co-inhibitory molecules belong to the B7/B7 ligand
family and the tumor necrosis factor (TNF)/TNF recep-
tor family. Their expression and functions are summa-
rized in Tables 1 and 2.
The ability to interfere with the inhibitory function of
checkpoint receptors CD152 (cytotoxic T lymphocyte
antigen-4) and CD279 (programmed death-1) in oncol-
ogy has proved successful. In 2011 the US Food and
Drug Administration (FDA) approved ipilimumab, an
αCD152 monoclonal antibody (Ab), for use in the clinic.
In patients with metastatic melanoma, ipilimumab was
found to effectively prolong survival and reduce metasta-
shown to have remarkable efficacy in cancer patients. In
patients with melanoma, nonsmall cell lung cancer, and
renal cell carcinoma, treatment with BMS-936558, a
CD279 blocking Ab, promoted anti-tumor responses [8].
Similarly, CT-011 (Cure Tech Ltd, Yavne, Israel), a hu-
manized αCD279 IgG1 monoclonal Ab, safely induced
remission in a subset of patients with hematologic
malignancies [8]. In patients with solid cancers, tumor re-
gression was noted following therapy with MDX-1106
(Medarex, Princeton, NJ, USA), an αCD279 IgG4 Ab, fur-
ther demonstrating that the CD279 pathway plays a cru-
cial role in cancer progression [2]. In addition to targeting
CD279, there are ongoing phase 1 clinical trials investigat-
ing the role of CD279 ligands: CD274/programmed death
ligand (PD-L)-1 in patients with solid tumors [Clinical-
Trials.gov:NCT00729664] and CD273/PD-L2 in stage IVLtd. The licensee has exclusive rights to distribute this article, in any medium, for 6
, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited. The Creative Commons Public Domain Dedication waiver (http://
applies to the data made available in this article, unless otherwise stated.
Table 1 B7/B7 ligand family members and functions
Molecule Expression Ligand/receptor Function
CD28 Resting T cells CD80 or CD86 on APCs Lowers TCR threshold
Delivers a co-stimulatory signal
Promotes T-cell proliferation, survival,
cytokine production, T cell-
dependent B cell functions [2]
CTLA-4/CD152 Resting/activating T cells Outcompetes CD28 for CD80/CD86
binding
Increased TCR threshold





PD-1/CD279 T cells, B cells, DCs, monocytes, NK T
cells, exhausted cells and Tregs
PD-L1 on APCs, B cells, and T cells.
PD-L2/CD273 on APCs. PD-L1/CD274
can also bind to CD80
Delivers an inhibitory signal
Suppresses Bcl-xl [2]
ICOS/CD278 Activated T cells, T follicular helper cells ICOSL/CD275 on APCs and B cells [2] Induces proliferation
Propagates germinal center reactions
Upregulates IL-10 production [2]
BTLA/CD272 B cells, DCs, Th1 cells, macrophages Herpes virus entry mediator [2] BTLA delivers an inhibitory signal via
ITIM and ITSM [2]
B7-H3/CD276 B cells, NK cells, T cells, activated
monocytes [2]
Unknown Co-inhibitory and co-stimulatory
functions. Suppress antitumor re-
sponses [2]
B7-H4/B7S1/B7x/Vtcn1 APCs, cancer cells, and mRNA expression
on nonhematopoietic tissue [2]
Unknown Reduces cell proliferation and T cell
interleukin-2 production [2]
B7-H6 Tumor cells [3] NKp30 Binds NKp30 on NK cells resulting in
interferon gamma and cytotoxic
function [2]
VISTA/Dies1/Gi24/PD-1H Highly expressed on murine myeloid
cells. Low expression on T cells [2]
Unknown Inhibits T-cell proliferation, reduces
CD44 and CD69 expression [2]
Increases cell motility [2]
APC, antigen presenting cell; BTLA, B and T lymphocyte attenuator; CTLA-4, cytotoxic T lymphocyte antigen-4; DC, dendritic cell; ICOS, inducible co-stimulator;
ICOSL, inducible co-stimulator ligand; ITIM, immunoreceptor tyrosine-based inhibition motif; ITSM, immunoreceptor tyrosine-based switch motif; NK, natural killer;
PD-1, programmed death-1; PD-L, programmed death ligand; TCR, T-cell receptor; Th, T helper; Treg, regulatory T cell.
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successes in manipulating CD152 and CD279/CD279 li-
gands in cancer provide proof of concept that targeting
these molecules can have profound effects on the human
immune response [8].
In contrast to the cancer studies, delivering an inhibi-
tory signal or blocking a stimulatory signal to achieve en-
dogenous immunosuppression is critical in autoimmune
diseases. This was first shown in 2005 when the FDA ap-
proved the humanized fusion protein CD152-IgG1 (abata-
cept) as a treatment for RA [10]. The aim of this review is
to discuss the function of co-stimulatory and co-inhibitory
molecules in the pathogenesis of SLE, RA, JIA, SS, psor-
iasis, and SSc, as well as their potential use as thera-
peutic targets.Systemic lupus erythematosus
SLE is a chronic inflammatory disease targeting multiple
organs including the skin, joints, kidneys, lungs, and
central nervous system. During disease, autoantibodies
to a spectrum of self-antigens, including nuclear antigens,
develop and form immune complexes in various tissues.
In the kidneys this complex formation results in glomer-
ulonephritis (GN) [11-13]. Current therapies in SLE focus
on both B-cell and T-cell targets. The αCD20 Ab rituxi-
mab (Genentech, South San Francisco, CA, USA) has
been effective anecdotally, but failed to achieve significant
benefit above background therapy in separate clinical trials
of nonrenal and renal SLE [14,15]. However, it is now
thought that these trials may have failed because the high
dosage of glucocorticoids used could have masked the
Table 2 Tumor necrosis factor/tumor necrosis factor receptor family members and functions
Molecule Expression Ligand/receptor Function
DR3 Lymphocytes Tumor necrosis factor-like cytokine 1A (TL1A)
expressed on APCs [4]
Delivers a co-inhibitory signal, induces cell
survival, prevents apoptosis [4,5]
4-1BB/CD137 Activated T cells, Tregs, DCs and
B cells
4-1BB ligand on DCs and B cells [6] 4-1BB induces CD8+ T-cell, NK T-cell and B-cell
survival [6]
Signaling back via 4-1BB ligand induces monocyte
activation [6]
OX40/CD134 Activated T cells OX40 ligand/CD252 on B cells, endothelial
cells, DCs and macrophages
OX40 increases CD4+ T-cell survival/effector
function [6]
OX40 impacts immunoregulation by reducing
interleukin-10 production by Tr1 and CD4+
Tregs [6]
CD27 Naïve T-cells, memory B cells,
NK T cells, NK cells [6]
CD70 on activated lymphocytes and DCs CD27–CD70 signaling on B cells propagates
germinal center formation and plasma cell
activities
Signaling on T cells results in proliferation and
cytokine production [6]
CD40 B cells CD154/CD40 ligand on T cells, T follicular
helper cells, endothelial and epithelial cells,
B cells or APCs [7]
CD154+ T cells permit germinal center formation
Signaling via CD40 on B cells induces B-cell
differentiation, isotype switching and
proliferation [7]
Signaling via CD40 on APCs, increases CD80
and CD86 expression [7]
APC, antigen presenting cell; DC, dendritic cell; NK, natural killer; Treg, regulatory T cell.
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hindered by the lack of a definitive target antigen, im-
paired T-cell homeostasis by reduced CD4+ regulatory
T-cell function, an altered T-cell repertoire that in turn
promotes autoantibody synthesis [18], inflammation
driven by T helper (Th)1 and Th2 responses [19], and
soluble mediators such as interferon (IFN) alpha [20].
Positive co-stimulation through CD28 and negative
regulation through CD152 are a major focus in designing
immunotherapeutic agents to treat lupus patients. There
is a wealth of evidence in murine models identifying inter-
actions between CD28 and CD152 and their receptors,
CD80 and CD86, as attractive clinical targets. In the spon-
taneous lupus-prone murine model NZBWF-1, where
females develop fatal GN, CD152-Ig therapy effectively re-
duces autoantibody production [21]. In combination with
cyclophosphamide, CD152-Ig effectively reverses nephritis
and prolongs survival in NZBWF-1 mice [22]. Further-
more, prenephritic mice treated with CD152-Ig and
αCD154 Ab have delayed disease onset and reduced
anti-double-stranded DNA Abs [23]. Administered as a
triple therapy combining CD152-Ig, cyclophosamide,
and αCD154 Ab, prolonged remission and the presence
of renal type II activated macrophages that serve as a
biomarker of remission have been noted in this model
[24]. In contrast to the success of CD152-Ig in murine
studies, the humanized CD152-IgG1 fusion protein aba-
tacept has been disappointing in the clinic due to anincrease in serious adverse events found in a subset of
patients in a phase IIb study [25]. A clinical trial investi-
gating the efficacy of the combination of abatacept and
cyclophosamide in human lupus nephritis is ongoing
[ClinicalTrials.gov:NCT00774852].
There are several other observations that the CD28–
CD152 axis is involved in the pathogenesis of lupus.
Elevated levels of soluble CD28 are found in serum from
lupus patients, which can inhibit T-cell proliferation
in vitro [26]. Whether these levels are active in tempering
disease is unknown. There is also an association between
polymorphisms in the CD152 gene and SLE susceptibility
in some ethnic groups [27]. How this polymorphism
impacts disease progression is unclear because CD152 ex-
pression itself does not appear to be aberrant in SLE pa-
tients. However, studies have shown that CD152 may be
functionally impaired in SLE, perhaps as a result of
αCD152 autoantibodies [28]. Recently, one study has
suggested that abatacept might be linked to regulatory
T-cell repopulation [29]. Expression of CD152 ligands
also appears to be relevant in SLE. High CD80 expres-
sion on CD4+ T cells correlates with disease severity
[30], and treatment with αCD80 Ab reduces disease sever-
ity in the pristine-induced murine model of disease [31].
The CD278 (inducible co-stimulator)–CD275 (indu-
cible co-stimulator ligand) co-stimulatory pathway may
play a role in SLE pathogenesis. In SLE patients, CD278
is expressed on renal lymphocytes and peripheral blood
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reduced on memory B cells, possibly due to recent inter-
actions with CD278+ T cells [32,33]. In vitro, CD278 and
CD3 stimulation leads to increased autoantibody syn-
thesis from SLE peripheral blood mononuclear cells,
indicating that CD278 contributes to disease and per-
turbed B-cell Ab responses [34]. This is further sup-
ported in vivo by reduced autoantibody production by
CD278–/– lupus-prone MRL/lpr mice [35]. In NZBWF-
1 mice, prophylactic and therapeutic treatment with
αCD275 Ab significantly reduced disease pathology [36],
indicative that both the receptor and ligand are involved
in perpetuating inflammation. The role of CD278 as a
therapeutic target in human SLE is currently being evalu-
ated in a phase Ib trial with AMG557, an αCD275 Ab
[ClinicalTrials.gov:NCT00774943].
CD279 is an inhibitory receptor expressed on activated
T cells that upon binding to CD274 (PD-L1) or CD273
(PD-L2) delivers a negative signal into the T cells [37]. In
SLE patients, polymorphisms in the CD279 gene are asso-
ciated with disease susceptibility [38]. In vivo, the role of
CD279 is evident by the development of GN in CD279–/–
mice bred onto the lupus-prone strain lpr/lpr [39]. In
NZBWF-1 mice, CD274 blockade increases CD4+CD279+
T cells and clinical pathology, demonstrating that blockade
of the CD279:CD274 axis exacerbates disease [40]. In
contrast, one study showed that αCD279 Ab treatment
is associated with increases in CD8+ and CD4+ regula-
tory T cells and protection from disease in NZBWF-1
mice [41,42]. Because of these contradictory results,
how the CD279 pathway signals in SLE remains un-
known. One explanation is that the αCD274 Ab acted as
a blocking Ab, which in turn would explain the increase
in effector CD279+CD4+ T cells that produce IFNγ and
perpetuate disease [40]. It is also possible that αCD279
Ab may delete CD279+ effector T cells, resulting in dis-
ease remission.
CD154 and its receptor, CD40, regulate both humoral
and cellular immunity. CD154+ activated T cells can trig-
ger B-cell activation, germinal center formation, long-lived
Ab responses, and dendritic cell activation to facilitate the
development of CD4+ and CD8+ T-cell responses [7].
Blocking this central co-stimulatory signal is an attractive
target in lupus. An increase in CD154 expression on SLE
lymphocytes correlates with disease severity in pediatric
patients [43]. In active SLE, CD154 is highly expressed on
lymphocytes and diminished in remission patients [44]. In
a separate study, CD154 expression on T cells was found
to induce CD80 on B cells, thus increasing their activation
status and further propagating disease [45]. High levels of
soluble CD154 have been detected in the serum of pa-
tients with advanced disease [46]. In vivo, αCD154 Ab
therapy in NZBWF-1 mice prevents the onset of GN
[47] and, when administered prior to the establishmentof GN, diminishes renal immune complex deposition
and prolongs survival [48]. Therapeutic intervention
with αCD154 Ab in this disease model also reduces dis-
ease severity and resolves proteinuria [48].
In spite of the success of αCD154 Ab in murine
models, the results of treatment in clinical trials are in-
conclusive [49]. In patients with active SLE, treatment
with IDEC-131, a humanized αCD154 Ab, did not signifi-
cantly improve disease scores or suppress anti-double-
stranded DNA Ab or complement consumption [49].
However, this finding is confounded by the high placebo
response in this trial due to the heterogeneity of SLE [49].
In a phase II trial in patients with proliferative lupus neph-
ritis, BG9588 (Biogen, Inc., Cambridge, MA, USA), another
αCD154 Ab, ameliorated disease activity, including pro-
teinuria, and diminished CD38+ Ab-secreting cells [50].
Unfortunately, hematuria and thromboembolic events
were reported in two subjects leading to concerns over the
safety of targeting CD154 and to early termination of
the trial [51]. Later studies have since reported that
αCD154 Ab contributes to atherosclerosis and pro-
thrombotic events [52]. This has prompted the reengi-
neering of αCD154 Ab for safe use in SLE preclinical
trials. Recently, researchers have shown that an αCD154
Ab containing a mutation in the IgG1 domain impairs
Fc effector function and reduces thromboembolism in
NZBWF-1 mice [53]. This observation suggests that fur-
ther development of the αCD154 Abs with these modifi-
cations could increase their safety.
CD134 (OX40), a member of the TNF receptor super-
family, is a co-stimulatory molecule expressed on acti-
vated T cells and has been examined in SLE. CD134
expression on peripheral blood T cells from patients
with lupus nephritis correlates with disease severity [30].
In the glomerular wall of lupus nephritis patients, CD134
expression on T cells and CD252 (OX40 ligand) expression
on renal cells have been reported [54]. To understand the
function of these molecules, in vitro assays have been
performed to examine the function of both CD134 and
CD252. For example, treatment of splenocytes from lupus-
prone BXSB mice with αCD252 Ab, in combination with
CD152-Ig, suppresses autoantibody production and proin-
flammatory cytokines [55]. Similarly, in vitro treatment of
peripheral blood mononuclear cells from SLE patients with
an αCD134 Ab reduces interleukin (IL)-4 and IL-10 and
enhances IFNγ production whereas CD134-Ig reduces
both Th1 and Th2 cytokines [56]. The method of targeting
CD134 can exert different outcomes and warrants further
investigation. For example, αCD134 Ab controls inflamma-
tion in lymph nodes while CD134-Ig prevented the onset
of GN [56]. Collectively, these studies show that the
CD134–CD252 pathway is involved in regulating inflam-
mation by reducing the production of cytokines such as
IL-4 and IL-10, known to perpetuate inflammation in SLE.
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The CD70–CD27 and CD137 (4-1BB)–CD137 ligand
(4-1BB ligand) co-stimulatory pathways belong to the
TNF/TNF receptor family and signal on activated T cells.
In SLE patients, impaired DNA methylation of CD70 on
T cells is associated with disease progression [57] and ex-
pression of CD27 on memory SLE B cells and plasma cells
correlates with disease severity [58,59]. At present, the
CD70–CD27 pathway has yet to be extensively examined
in murine lupus models. Several in vivo studies have in-
vestigated the role of CD137–CD137 ligand in SLE.
CD137–/– mice bred on a MRL/lpr background have in-
creased autoantibody production, pathogenic T cells, and
reduced survival [60]. Additionally, treatment of MRL/lpr
mice with αCD137 Ab reduced CD4+ T cells, GN, and
germinal center formation, as well as prolonging survival
[61]. Similarly, αCD137 Ab therapy reduces disease sever-
ity in the NZBWF-1 model [62]. No clinical trials have
been reported with either pathway in SLE.
Rheumatoid arthritis
RA is a chronic systemic inflammatory disease charac-
terized by destructive synovitis that, left undiagnosed, re-
sults in significant pain, deformity, and disability. RA
predominately manifests in females and affects about
0.24% of the population [63]. Tissue inflammation and
damage is mediated through several cell types, including
T cells, B cells, monocytes, macrophages, and osteoclasts.
Treatment of RA has been revolutionized by the use of bi-
ologics, including TNF inhibitors, rituximab, abatacept,
and others beyond standard therapy, generally consisting
of methotrexate.
One of the main pathways examined in RA involves
CD28 and CD152 interactions with their binding part-
ners, CD80 and CD86. Certain CD152 polymorphisms
are associated with an increased risk of developing RA
[64]. Soluble CD152 expression also correlates with dis-
ease severity, and membrane expression of CD152 on
regulatory T cells is reduced [65,66]. Abatacept is effective
in treating disease alone or in combination with metho-
trexate. Patients with low baseline levels of CD8+CD28– T
cells are more likely to achieve full remission when treated
with abatacept [67]. Additionally, the frequency of CD4
+CD28– T cells decreases with treatment but it is uncer-
tain whether this is a direct effect [68].
Other inhibitory B7 family members are also relevant
in RA. CD279 polymorphisms are associated with in-
creased susceptibility to disease, and soluble and mem-
brane expression of CD279 is decreased in RA patients
[69,70]. In mouse RA models, deficiency of CD279 or
CD274 exacerbated disease [71,72]. Furthermore, treat-
ment of mice with a CD274-Ig fusion protein marginally
attenuates collagen-induced arthritis (CIA) [73]. Highlevels of soluble B7-H4, a B7 family inhibitory ligand,
are associated with disease severity in RA patients as
well as in murine models [74,75]. Both deficiency of B7-
H4 and transgenically increased soluble expression of
B7-H4 in CIA leads to accelerated disease, and treat-
ment with a B7-H4-Ig fusion protein attenuates CIA
[75]. AMP-110, a B7-H4-Ig fusion protein, is currently
in a phase I study for use in RA [ClinicalTrials.gov:
NTC01878123]. Co-inhibitory ligand CD272 (BTLA)
and its receptor HVEM are found in affected synovium of
RA patients [76,77]. Treatment of mice with HVEM-Ig in-
creased disease severity in CIA [78]. No clinical trials in-
volving BTLA and HVEM have been documented in RA.
The CD40 and CD154 pathway is implicated in RA
pathogenesis. Some CD40 gene polymorphisms are as-
sociated with increased RA susceptibility. In addition,
CD154 expression is increased in blood and synovial
fluid T cells from RA patients [79,80]. IgM and IgG Abs
against rheumatoid factor also correlate with increased
levels of soluble CD154 [81]. Females with disease have
greater expression of CD154 on CD4 T cells in compari-
son with healthy female controls, and the CD154 pro-
moter is hypomethylated in females, but not males, with
RA [82]. In CIA, αCD40 Ab treatment exacerbates dis-
ease, and αCD154 Ab and siRNA silencing of CD40 at-
tenuates disease [83-86].
Other TNF superfamily checkpoint regulators are as-
sociated with RA. Soluble CD137 and CD137 ligand are
also increased in RA patients in comparison with healthy
controls, and αCD137 Ab treatment decreases CIA se-
verity [87-89]. In addition, T cells expressing CD134
accumulate in effected synovial joints of RA patients. In
CIA, both αCD134 Ab treatment and CD134-Ig treat-
ment can attenuate disease [90-93]. This observation
suggests that blocking engagement of CD134 with its
ligand is responsible for this effect. CD70 is also overex-
pressed on CD4+CD28– T cells from RA patients, and
treatment of CIA with αCD70 Ab reduced autoantibody
titers and disease severity [94,95]. Currently there are no
clinical trials of these molecules in RA.
Juvenile idiopathic arthritis
Immune checkpoint regulators are also implicated in the
pathogenesis of JIA. Patients have an increased propor-
tion of activated CD4+ and CD8+ T cells expressing
CD25 and CD69, and lacking CD28 expression. There is
a concomitant decrease in the naïve T-cell pool with
shortened telomere length, suggestive of premature aging
of this cell population [96]. In the CD8 T-cell compart-
ment, CD28 negative cells have enhanced CD31 expres-
sion, allowing T cell receptor-independent activation of
these cells [97]. In comparison with healthy controls, JIA
patients have reduced numbers of dendritic cells in the
blood and increased numbers in the synovial fluid. The
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CD80, CD86, and CD40 in comparison with those in the
blood, suggesting they are actively promoting inflamma-
tion in the joint [98]. Abatacept is FDA approved for the
treatment of JIA alone and in combination with metho-
trexate on the basis of a double-blind withdrawal study
[99]. Additional potential targets in this disease are B7-
H4, identified as a susceptibility gene, and CD154, whose
soluble levels are elevated in JIA [100,101].
Sjogren’s syndrome
SS is an autoimmune systemic disorder that can occur
by itself or in combination with other connective tissue
diseases. Clinically, SS is characterized by dry eyes and
dry mouth. This results from impaired exocrine function
of the lacrimal and salivary glands, respectively, due to
damage from a predominantly CD4+ T-cell infiltration
[102]. The serologic hallmarks of SS include autoanti-
bodies directed against ribonucleoprotein components
SS-A (Ro) and/or SS-B (La) [103].
CD28 and CD152 interactions with CD80 and CD86
represent the best studied immune checkpoint regula-
tors in SS. In SS patients, high levels of soluble CD28
are found in the serum and loss of expression on T cells
is detected [26,104] and, in vitro, soluble CD28 inhibits
T-cell proliferation in response to αCD3 [26]. This is
further complimented in vivo in NFS/sld mice, a model
of SS where CD4+CD28– T cells in predisease mice ex-
press mRNA for IL-4, IL-10, and transforming growth
factor beta, and prevent autoimmune lesion formation
when adoptively transferred [105]. In SS, CD152 poly-
morphisms are linked to disease susceptibility and auto-
antibody production [106,107]. At the transcriptional
level CD152 mRNA is found in salivary gland tissue, and
αCD152 Abs are detected in the serum of SS patients
suggesting the presence of this protein [28,108].
In addition to normal expression on antigen present-
ing cells, CD80 and CD86 are expressed on salivary
gland epithelial cells and duct cells, and can be further
upregulated in patients with sialoadentis with IFNγ
[109,110]. On duct cells, CD80 and CD86 expression is as-
sociated with Th1 cytokines (IL-2 and IFNγ) and Th2 cy-
tokines (IL-4 and IL-5), respectively [111]. This suggests
that duct cells and other nonhematopoietic cells in the sal-
ivary glands express checkpoint regulator proteins that in-
fluence the development of inflammation. Therapeutically,
NFS/sld mice treated with αCD86 Ab show reduced auto-
antibody production, T-cell activation, and a lack of auto-
immune lesions, suggesting that the therapy eliminates
CD28 co-stimulation [112]. In C57BL/6.NOD-Aec1Aec2
mice, another model for SS, treatment with an adeno-
associated virus-2 vector encoding a CD152-Ig fusion pro-
tein reduced cell infiltration and Th1 and Th17 cytokine
production [113], probably by binding to CD80 and CD86and preventing co-stimulation through CD28. At present,
a phase II study is currently recruiting inflammatory arth-
ritis patients with SS to investigate the efficacy of abata-
cept [ClinicalTrials.gov:NCT02027298].
A few additional B7 family members have been exam-
ined in SS. For example, increased CD279 mRNA levels
have been found in SS salivary gland tissue [108]. T cells
in inflamed salivary glands express elevated levels of
CD279, and CD274 expression on epithelial cells can be
induced by IFNγ [114]. Since expression is intact, one
speculation is that signaling through this co-inhibitory
molecule pair is defective, because this potent negative
checkpoint regulator pathway would be expected to con-
trol inflammatory T-cell responses in such a setting. One
study has found in SS patients that salivary gland epithelial
cells expressing CD275 can differentiate CD4+ T cells into
T-follicular helper cells [115]. In one murine model, in-
creased cell infiltration into the salivary glands has been
reported in CD272–/– mice [116]. These B7 molecules
therefore play a role in determining the outcome of T-cell
responses in SS and warrant further preclinical studies.
TNF superfamily members are also implicated in SS.
Soluble CD154 is increased in the serum of SS patients
and CD40:CD154 engagement can induce apoptosis of
salivary gland cells [117,118]. However, treatment of non-
obese diabetic mice with a vector containing CD40-Ig
showed no significant reduction in inflammation in the
salivary glands [119]. One study has linked CD252 poly-
morphisms with B-cell activation in patients with primary
SS [120]. Similarly, the CD27–CD70 pathway is associated
with B-cell abnormalities in SS. This association is demon-
strated by the presence of CD27+ memory B cells in in-
flamed salivary glands [121,122] and overexpression of
CD70 on CD4+ T cells due to hypomethylation of the
CD70 promoter in SS patients [123].Psoriasis
Psoriasis is a chronic inflammatory skin disease charac-
terized by hyperproliferation of kertinocytes, affecting
approximately 2% of the population [124]. Some patients
also have associated psoriatic arthritis, a destructive
spondyloarthropathy. Treatments for psoriasis vary con-
siderably depending on disease severity and the presence
or absence of arthritis. These treatments include topical
or systemic agents such as corticosteroids, retinoids, vita-
min D analogs, ultraviolet light, methotrexate, cyclosporin,
TNF inhibitors, and αIL-12/23 (p40) [125]. Little work has
been done examining the role of co-stimulatory and co-
inhibitory molecules during disease. However, studies with
abatacept have shown that treatment can result in clinical
improvement in patients with severe psoriasis and psori-
atic arthritis [126-130]. In addition, elevated levels of
CD154 are found on T cells from both psoriasis and
Figure 1 Current in vivo immune checkpoint receptor therapies in rheumatic diseases. T-cell activation requires two signals. The first is via
the T-cell receptor (TCR), where peptide is presented by the major histocompatibility complex (MHC) on responder cells. The second involves a
network of co-inhibitory and co-stimulatory molecules pathways such as CD80/CD86–CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4), inducible
co-stimulator (ICOS)–ICOS ligand (ICOSL), programmed death-1 (PD-1), programme death ligand-1/2 (PD-L1/PD-L2), 4-1BB–4-1BB ligand (4-1BBL),
CD40–CD154 ligand, OX40–OX40 ligand and CD27–CD70. This diagram summarizes current therapies for manipulating these pathways to
suppress disease in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), psoriasis (Ps), and systemic sclerosis
(SSc). Ab, antibody; CTX, cyclophosphamide; JIA, juvenile idiopathic arthritis.
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treatment may be effective in this disease [131,132].
Systemic sclerosis
SSc is a complex autoimmune disease characterized by
inflammation, vascular abnormalities, and fibrosis in the
skin and internal organs and is more common in females
than males. Early skin lesions demonstrate infiltration of
activated CD4+ T cells, CD8+ T cells, monocytes, and
macrophages [133-135]. In addition, autoantibodies are
present that can directly promote fibrosis, and the pat-
tern of antinuclear antibodies present can predict disease
progression [136-138]. TNF superfamily co-stimulatory
molecules have been associated with disease. Demethyla-
tion of CD154 regulatory elements in females is associ-
ated with CD154 overexpression on CD4+ T cells [139].
Patients also exhibit elevated plasma levels of soluble
CD154. In bleomycin-induced skin sclerosis, a murine
model of the disease, prophylactic αCD154 Ab treat-
ment attenuated disease [140]. In addition, CD70 is
overexpressed in T cells from patients with SSc and this
correlates with demethylation of its promoter region
[141]. Gene polymorphisms in CD134 are associated
with increased susceptibility to SSc [142]. These obser-
vations suggest that therapies targeting CD154, CD70,
and CD134 may be worth further investigation for the
treatment of disease.
Conclusions
In summary, checkpoint regulators represent viable im-
munotherapeutic targets for the treatment of both auto-
immunity and cancer. A wealth of both mouse and
human data indicate that co-stimulatory and co-inhibitory
molecules are critical in a number of autoimmune rheum-
atic diseases (Figure 1). In addition, interventions in mul-
tiple murine models utilizing several of these pathways,
either by blocking co-stimulatory receptors or by engaging
inhibitory receptors, have profound therapeutic effects.
However, abatacept is the only agent to achieve FDA ap-
proval in the autoimmune human diseases RA and JIA.
To date, these findings have not translated into safe and
effective therapy for other diseases. In light of the veritable
explosion of effective treatments for RA and the approval
of more agents for the treatment of psoriatic arthritis, a
particular disappointment is the limited progress on this
front in SLE. Expectations are still high that this will be
achieved within the next few years. The current leading
contenders for a successful agent in SLE from a check-
point regulator perspective are αCD275, abatacept, or a
modified αCD154 Ab. Perhaps SS and certainly SSc re-
main even more daunting disease targets. The intense
ongoing investigation in this already fruitful area will un-
doubtedly produce more candidates for clinical trials in
SLE and other rheumatic diseases in the near future.Abbreviations
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